Health Catalyst (NASDAQ:HCAT) Shares Down 7.7%
Health Catalyst (NASDAQ:HCAT) Shares Down 7.7%
Health Catalyst, Inc. (NASDAQ:HCAT – Get Rating) shares dropped 7.7% on Thursday . The company traded as low as $9.24 and last traded at $9.27. Approximately 11,230 shares traded hands during trading, a decline of 99% from the average daily volume of 1,135,162 shares. The stock had previously closed at $10.04.
健康催化剂公司(纳斯达克代码：HCAT-GET Rating)股价周四下跌7.7%。该公司股价低至9.24美元，最新报9.27美元。约有11,230股股票在交易中成交，较1,135,162股的日均成交量下降了99%。该股此前收盘价为10.04美元。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
HCAT has been the topic of a number of research reports. KeyCorp started coverage on shares of Health Catalyst in a report on Thursday, September 15th. They set a "sector weight" rating on the stock. The Goldman Sachs Group dropped their target price on shares of Health Catalyst from $29.00 to $18.00 and set a "buy" rating on the stock in a research report on Wednesday, August 10th. Piper Sandler downgraded shares of Health Catalyst from an "overweight" rating to a "neutral" rating and lowered their price objective for the stock from $21.00 to $11.00 in a report on Tuesday, September 13th. Stifel Nicolaus downgraded shares of Health Catalyst from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $27.00 to $16.00 in a report on Friday, August 5th. Finally, JPMorgan Chase & Co. downgraded shares of Health Catalyst from an "overweight" rating to a "neutral" rating and lowered their price objective for the stock from $20.00 to $16.00 in a report on Friday, August 5th. Four research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $25.92.
HCAT已成为许多研究报告的主题。KeyCorp在9月15日星期四的一份报告中开始报道Health Catalyst的股票。他们为该股设定了“行业权重”评级。8月10日，周三，高盛夫妇在一份研究报告中将Health Catalyst的目标价从29.00美元下调至18.00美元，并对该股设定了“买入”评级。在9月13日星期二的一份报告中，派珀·桑德勒将Health Catalyst的股票评级从增持下调至中性，并将该股的目标价从21.00美元下调至11.00美元。在8月5日星期五的一份报告中，Stifel Nicolaus将Health Catalyst的股票评级从“买入”下调至“持有”，并将其股票目标价从27.00美元下调至16.00美元。最后，在8月5日星期五的一份报告中，摩根大通将Health Catalyst的股票评级从增持下调至中性，并将该股的目标价从20.00美元下调至16.00美元。4位研究分析师对该股的评级为持有，8位分析师给出了买入评级，一位分析师给出了强烈的买入评级。根据MarketBeat.com的数据，该股目前的平均评级为“适度买入”，共识目标价为25.92美元。
Health Catalyst Stock Down 7.4 %
Health Catalyst股价下跌7.4%
The stock has a market cap of $508.92 million, a P/E ratio of -3.19 and a beta of 1.23. The business's 50-day simple moving average is $13.20 and its two-hundred day simple moving average is $16.71.
该股市值为5.0892亿美元，市盈率为-3.19，贝塔系数为1.23。该业务的50日简单移动均线切入位为13.20美元，200日简单移动均线切入位为16.71美元。
Insider Transactions at Health Catalyst
Health Catalyst的内幕交易
In other news, Director Duncan Gallagher purchased 8,400 shares of the stock in a transaction dated Thursday, August 18th. The shares were purchased at an average cost of $11.69 per share, with a total value of $98,196.00. Following the completion of the acquisition, the director now owns 28,805 shares in the company, valued at approximately $336,730.45. The transaction was disclosed in a document filed with the SEC, which is available at this link. Over the last ninety days, insiders have sold 1,964 shares of company stock valued at $26,306. 1.50% of the stock is currently owned by corporate insiders.
其他新闻方面，董事邓肯·加拉格尔在一笔日期为8月18日(星期四)的交易中购买了8,400股该公司股票。这些股票的平均价格为每股11.69美元，总价值为98,196.00美元。收购完成后，董事现在拥有该公司28,805股，价值约336,730.45美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可在以下网址获得这个环节。在过去的90天里，内部人士出售了1,964股公司股票，价值26,306美元。目前该公司1.50%的股份由企业内部人士持有。
Institutional Investors Weigh In On Health Catalyst
机构投资者看好Health Catalyst
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers raised its stake in Health Catalyst by 0.8% in the fourth quarter. Rhumbline Advisers now owns 49,095 shares of the company's stock valued at $1,945,000 after purchasing an additional 409 shares in the last quarter. Arizona State Retirement System raised its stake in Health Catalyst by 6.1% in the second quarter. Arizona State Retirement System now owns 12,696 shares of the company's stock valued at $184,000 after purchasing an additional 735 shares in the last quarter. Fairfield Bush & CO. purchased a new stake in Health Catalyst in the first quarter valued at approximately $25,000. Manchester Capital Management LLC raised its stake in Health Catalyst by 667.5% in the first quarter. Manchester Capital Management LLC now owns 1,159 shares of the company's stock valued at $30,000 after purchasing an additional 1,008 shares in the last quarter. Finally, US Bancorp DE raised its stake in Health Catalyst by 14.0% in the first quarter. US Bancorp DE now owns 9,260 shares of the company's stock valued at $242,000 after purchasing an additional 1,139 shares in the last quarter. 96.58% of the stock is owned by hedge funds and other institutional investors.
一些机构投资者和对冲基金最近买卖了该股的股票。Rhumbline Advisers在第四季度将其在Health Catalyst的持股比例提高了0.8%。Rhumbline Advisers在上个季度又购买了409股后，现在拥有49,095股该公司股票，价值1,945,000美元。亚利桑那州退休系统在第二季度将其在Health Catalyst的持股增加了6.1%。亚利桑那州退休系统现在拥有12,696股该公司的股票，价值18.4万美元，上个季度又购买了735股。费尔菲尔德·布什公司在第一季度购买了Health Catalyst的新股份，价值约为25,000美元。曼彻斯特资本管理有限责任公司在第一季度增持了667.5%的Health Catalyst股份。曼彻斯特资本管理公司现在拥有1,159股该公司的股票，价值30,000美元，在上个季度又购买了1,008股。最后，US Bancorp DE在第一季度将其在Health Catalyst的持股比例提高了14.0%。US Bancorp DE现在拥有该公司9260股股票，价值24.2万美元，此前在上个季度又购买了1139股。96.58%的股票由对冲基金和其他机构投资者持有。
Health Catalyst Company Profile
Health Catalyst公司简介
(Get Rating)
(获取评级)
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights.
Health Catalyst，Inc.为医疗保健组织提供数据和分析技术和服务。其产品包括数据和分析平台，这是一个面向医疗保健部门的商业级数据和分析平台；人工智能和数据科学，提供将人工智能集成到现有商业智能工具中，提高分析准确性；人口健康管理，确定整个医疗连续体系的改善，以及成功和自动化工作流的可行指导；金融转型，提供成本计算和劳动生产率洞察和收入获取；使用临床质量和患者安全数据、分析和专家服务来改进质量和安全；以及国家数据生态系统，用于思想领先和相互知识交流，以通过下一代洞察来转变医疗交付。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Health Catalyst (HCAT)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase's Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 免费获取StockNews.com关于Health Catalyst(HCAT)的研究报告
- 这些机构持有达顿餐饮国际公司的股份
- 斯蒂尔凯斯的收益说明了他重返办公室的原因吗？
- 住房建设的黄金时代已经结束了吗？
- 这三大股利支付者也拥有强劲的价格增长
- 天然气价格继续回升，这些股票应该会受益
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.
接受每日健康催化剂的新闻和评级-在下面输入您的电子邮件地址，以通过MarketBeat.com的免费每日电子邮件时事通讯接收对Health Catalyst和相关公司的最新新闻和分析师评级的每日简要摘要。